首页分享 Research progress on regulating tumor immune escape mechanism of edible and medicinal fungal polysaccharides

Research progress on regulating tumor immune escape mechanism of edible and medicinal fungal polysaccharides

来源：花匠小妙招时间：2025-01-27 02:03

[1] Vasquez L, Castro D, León J, Beltrán B. Inmunoterapia en cáncer: de los inicios al premio Nobel. Revista Peruana De Medicina Experimental Y Salud Publica, 2020, 37(1): 115-121. DOI:10.17843/rpmesp.2020.371.4329 [2] Li MX, Luo T, Huang Y, Su JY, Li D, Chen XH, Zhang YF, Huang LH, Li SX, Jiao CW, Li WZ, Xie YZ, Li WD. Polysaccharide from Pycnoporus sanguineus ameliorates dextran sulfate sodium-induced colitis via helper T cells repertoire modulation and autophagy suppression. Phytotherapy Research, 2020, 34(10): 2649-2664. DOI:10.1002/ptr.6695 [3] Li XM, Xie YZ, Yang BB. Characterizing novel anti-oncogenic triterpenoids from ganoderma. Cell Cycle, 2018, 17(5): 527-528. DOI:10.1080/15384101.2017.1315493 [4] Li XM, Wu QP, Xie YZ, Ding YR, Du WW, Sdiri M, Yang BB. Ergosterol purified from medicinal mushroom Amauroderma rude inhibits cancer growth in vitro and in vivo by up-regulating multiple tumor suppressors. Oncotarget, 2015, 6(19): 17832-17846. DOI:10.18632/oncotarget.4026 [5] 李向敏. 皱盖假芝和灵芝孢子中甾醇类化合物抗肿瘤作用机制研究. 华南理工大学博士学位论文, 2015. [6] Fu YJ, Gao X, Tian Z, Li RJ, Wang MX, Tian JX, Zhang BH, Yang LP. Recearch progress on immunomodulatory effects of lentinan on tumor microenvironment. Drugs & Clinic, 2019, 34(9): 2870-2875. (in Chinese)
符映均, 高欣, 田振, 李儒杰, 王明莃, 田佳鑫, 张碧华, 杨莉萍. 香菇多糖对肿瘤微环境免疫调节作用的研究进展. 现代药物与临床, 2019, 34(9): 2870-2875. [7] Wu LJ, Qi M, Li N, Lei YH, Zhang DM, Chen JX. Curative efficacy of lentinan injection combined with CHOP chemotherapy in the treatment of diffuse large B cell lymphoma and its effects on the Bcl-6, Ki-67, VEGF, β2-MG expressions. Progress in Modern Biomedicine, 2018, 18(11): 2122-2126, 2149. (in Chinese)
吴必嘉, 龚峻梅, 陈娟娟, 黄斯勇, 高飞. 香菇多糖注射液联合CHOP化疗治疗弥漫性大B细胞淋巴瘤的疗效及对Bcl-6、Ki-67、VEGF、β2-MG表达的影响. 现代生物医学进展, 2018, 18(11): 2122-2126, 2149. [8] Deng BJ, Gong JM, Chen JJ, Huang SY, Gao F. Natural products and their derivatives: promising modulators of tumor immunotherapy. Journal of Leukocyte Biology, 2020, 108(2): 493-508. DOI:10.1002/JLB.3MR0320-444R [9] Wang YX, Han JG. Pay attention to the therapeutic effect of ganoderma sinense polysaccharide tablets on tumor China. Health Care and Nutrition, 2013(9): 5343. (in Chinese)
王永霞, 韩金刚. 重视紫芝多糖片对肿瘤的治疗作用. 中国保健营养, 2013(9): 5343. [10] Liu M, Ju CY, Liu Y, Xiao XJ, Zhang LM, Sun W, Zhu YM, Li L, Zhu YL. The efficacy and safety of Ganoderma lucidum polysaccharides in the treatment of depression. Capital Food Medicine, 2016, 23(12): 53-55. (in Chinese)
刘勐, 居春阳, 刘羽, 肖兴军, 张丽梅, 孙威, 朱延梅, 李磊, 朱雨岚. 灵孢多糖注射液联合西酞普兰治疗抑郁症的疗效和安全性研究. 首都食品与医药, 2016, 23(12): 53-55. [11] Cör D, Knez Ž, Knez Hrnčič M. Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of Ganoderma lucidum terpenoids and polysaccharides: a review. Molecules, 2018, 23(3): 649. DOI:10.3390/molecules23030649 [12] Yang DY, Jiao Y, Du ZJ, Hu XJ, Liu F. Therapeutic effects of polyporus polysaccharide injection combined with cisplatin intraperitoneal injection on seroperitoneum due to gastric cancer. Hebei Medical Journal, 2018, 40(5): 725-727, 731. (in Chinese)
杨冬野, 焦洋, 杜志坚, 胡晓杰, 刘飞. 猪苓多糖注射液联合顺铂腹腔给药治疗胃癌腹腔积液患者的疗效观察. 河北医药, 2018, 40(5): 725-727, 731. [13] Li XQ, Zhang BB, Zhang MK, Song JW, Wang XL. Coriolus versicolor polysaccharide combined with XELOX regimen in the treatment of advanced colorectal cancer. World Latest Medicine Information, 2019, 19(99): 230, 235. (in Chinese)
李秀芹, 张斌斌, 张明奎, 宋家伟, 王雪莲. 云芝多糖联合XELOX方案在晚期大肠癌治疗中的疗效观察. 世界最新医学信息文摘, 2019, 19(99): 230, 235. [14] Pang LF. Clinical study about parenteral solution of Tremella polysaccharide improving quality of life of patients with liver cancer during chemotherapy. Journal of Hubei University of Chinese Medicine, 2014, 16(4): 85-86. (in Chinese)
庞良芳. 银耳孢糖提高肝癌化疗患者生存质量的研究. 湖北中医药大学学报, 2014, 16(4): 85-86. DOI:10.3969/j.issn.1008-987x.2014.04.31 [15] 史春雨. 复方茯苓多糖口服液抗肿瘤作用机制研究. 南方医科大学硕士学位论文, 2018. [16] Mao GH, Zhang ZH, Fei F, Ding YY, Zhang WJ, Chen H, Ali SS, Zhao T, Feng WW, Wu XY, Yang LQ. Effect of Grifola frondosa polysaccharide on anti-tumor activity in combination with 5-Fu in Heps-bearing mice. International Journal of Biological Macromolecules, 2019, 121: 930-935. DOI:10.1016/j.ijbiomac.2018.10.073 [17] Jiang XJ, Wang J, Deng XY, Xiong F, Ge JS, Xiang B, Wu X, Ma J, Zhou M, Li XL, Li Y, Li GY, Xiong W, Guo C, Zeng ZY. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular Cancer, 2019, 18(1): 10. DOI:10.1186/s12943-018-0928-4 [18] Wang YA, Li XL, Mo YZ, Fan CM, Tang L, Xiong F, Guo C, Xiang B, Zhou M, Ma J, Huang X, Wu X, Li Y, Li GY, Zeng ZY, Xiong W. Effects of tumor metabolic microenvironment on regulatory T cells. Molecular Cancer, 2018, 17(1): 168. DOI:10.1186/s12943-018-0913-y [19] Wen MJ, Yang S, Wang QH, Wen CL, Huang XF, Wang X, Zhou PH. Targeting immune checkpoints to treat cancer-The 2018 Nobel prize in physiology or medicine. Progress in Physiological Sciences, 2019, 50(4): 315-321. (in Chinese)
温铭杰, 杨硕, 王惊华, 韦春莲, 黄雪峰, 王玺, 周鹏辉. 癌症治疗的新支柱-免疫检查点疗法——2018年诺贝尔生理学或医学奖. 生理科学进展, 2019, 50(4): 315-321. DOI:10.3969/j.issn.0559-7765.2019.04.017 [20] Hu M, Liu QY. Key factors limiting the efficacy of immune-checkpoint blockade and research progress on combined anti-tumor strategies. Chinese Journal of Cancer Biotherapy, 2019, 26(9): 933-940. (in Chinese)
胡淼, 刘秋燕. 限制免疫检查点阻断疗效的关键因素及联合抗肿瘤对策的研究进展. 中国肿瘤生物治疗杂志, 2019, 26(9): 933-940. [21] Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities. Nature Reviews Clinical Oncology, 2020, 17(9): 527-540. DOI:10.1038/s41571-020-0363-5 [22] Wang QT, Nie Y, Sun SN, Lin T, Han RJ, Jiang J, Li Z, Li JQ, Xiao YP, Fan YY, Yuan XH, Zhang H, Zhao BB, Zeng M, Li SY, Liao HX, Zhang J, He YW. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunology, Immunotherapy, 2020, 69(7): 1375-1387. DOI:10.1007/s00262-020-02496-w [23] Darapu H, Li P, Paluri R. SUN-332 autoimmune endocrinopathies associated with CTLA-4 inhibitors: a meta-analysis. Journal of the Endocrine Society, 2019, 3(S1): SUN-332. [24] Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I. Deciphering CD137(4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. European Journal of Immunology, 2016, 46(3): 513-522. DOI:10.1002/eji.201445388 [25] Mastracci L, Fontana V, Queirolo P, Carosio R, Grillo F, Morabito A, Banelli B, Tanda E, Boutros A, Dozin B, Gualco M, Salvi S, Romani M, Spagnolo F, Poggi A, Pistillo MP. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. Cancer Immunology, Immunotherapy, 2020, 69(4): 653-662. DOI:10.1007/s00262-020-02494-y [26] Fujii R, Friedman ER, Richards J, Tsang KY, Heery CR, Schlom J, Hodge JW. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget, 2016, 7(23): 33498-33511. DOI:10.18632/oncotarget.9256 [27] Grenga I, Donahue RN, Lepone LM, Richards J, Schlom J. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clinical & Translational Immunology, 2016, 5(5): e83. [28] Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity, 2016, 44(5): 989-1004. DOI:10.1016/j.immuni.2016.05.001 [29] Kang C, Syed YY. Atezolizumab (in combination with Nab-paclitaxel): a review in advanced triple-negative breast cancer. Drugs, 2020, 80(6): 601-607. DOI:10.1007/s40265-020-01295-y [30] Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I, Nanda R, Chung C, Cassier P, Delord JP, Gordon M, Li YJ, Liu B, O'Hear C, Fasso M, Molinero L, Emens LA. Abstract 2986:Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses. Cancer Research, 2017, 77(S13): 2986-2986. [31] Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, Modi S. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2(HER2)-positive metastatic breast cancer. Breast Cancer Research, 2017, 19(1): 89. DOI:10.1186/s13058-017-0879-5 [32] Kok M, Voorwerk L, Horlings H, Sikorska K, Van Der Vijver K, Slagter M, Warren S, Ong S, Wiersma T, Russell N, Lalezari F, de Maaker M, Kemper I, Mandjes IA, Chalabi M, Sonke GS, Salgado R, Linn SC, Schumacher T, Blank CU. Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational data. American Society of Clinical Oncology, 2018, 36(S15): 1012. [33] Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun JW, Chen L, Chen YS, Zhu GF, Yin WW, Zheng LH, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen LP. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell, 2019, 176(1/2): 334-347.e12. [34] Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology, 2016, 13(5): 273-290. DOI:10.1038/nrclinonc.2016.25 [35] Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 1999, 11(2): 141-151. DOI:10.1016/S1074-7613(00)80089-8 [36] Chen LP, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 1992, 71(7): 1093-1102. DOI:10.1016/S0092-8674(05)80059-5 [37] Ina H, Yoneda M, Kanda M, Kodera Y, Kabeya M, Yuasa S, Kataoka T, Furuta R, Ina K. Lentinan, a shiitake mushroom β-glucan, stimulates tumor-specific adaptive immunity through PD-L1 down-regulation in gastric cancer cells. Medicinal Chemistry, 2016, 6(12): 710-714. [38] Su JY, Su L, Li D, Shuai O, Zhang YF, Liang HJ, Jiao CW, Xu ZC, Lai Y, Xie YZ. Antitumor activity of extract from the sporoderm-breaking spore of Ganoderma lucidum: restoration on exhausted cytotoxic T cell with gut microbiota remodeling. Frontiers in Immunology, 2018, 9: 1765. DOI:10.3389/fimmu.2018.01765 [39] Su JY, Li D, Chen QJ, Li MX, Su L, Luo T, Liang DL, Lai GX, Shuai O, Jiao CW, Wu QP, Xie YZ, Zhou XX. Corrigendum: anti-breast cancer enhancement of a polysaccharide from spore of Ganoderma lucidum with paclitaxel: suppression on tumor metabolism with gut microbiota reshaping. Frontiers in Immunology, 2019, 10: 1224. DOI:10.3389/fimmu.2019.01224 [40] Wang G, Wang L, Zhou JL, Xu XX. The possible role of PD-1 protein in Ganoderma lucidum-mediated immunomodulation and cancer treatment. Integrative Cancer Therapies, 2019, 18: 1-13. DOI:10.1177/1534735419880275 [41] Fan LA, Yan WH. Non-classical MHC class I molecules and immune regulation. Shanghai Journal of Immunology, 2003, 23(5): 289-292. (in Chinese)
范丽安, 颜卫华. 非经典MHC I类分子与免疫调节. 上海免疫学杂志, 2003, 23(5): 289-292. DOI:10.3969/j.issn.1001-2478.2003.05.001 [42] 骆亚莉, 刘永琦, 安方玉, 张利英, 李亚玲, 颜春鲁, 冯彩琴, 李研. 肿瘤免疫逃逸机制研究进展//第十三届全国免疫学学术大会摘要汇编. 上海: 中国免疫学会, 2018. [43] Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Li XF, Li XJ, Li M, Xing EH, Song YX, Jia J, Li WD. Enhanced MHC class I and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides. Journal of Drug Targeting, 2012, 20(7): 582-592. DOI:10.3109/1061186X.2012.697167 [44] Masuda Y, Nakayama Y, Tanaka A, Naito K, Konishi M. Antitumor activity of orally administered maitake α-glucan by stimulating antitumor immune response in murine tumor. PLoS ONE, 2017, 12(3): e0173621. DOI:10.1371/journal.pone.0173621 [45] Pi CC, Chu CL, Lu CY, Zhuang YJ, Wang CL, Yu YH, Wang HY, Lin CC, Chen CJ. Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo. Vaccine, 2014, 32(3): 401-408. DOI:10.1016/j.vaccine.2013.11.027 [46] Zhang BL, Sun T, Xue LY, Han XH, Zhang BL, Lu N, Shi YK, Tan W, Zhou YF, Zhao D, Zhang XM, Guo YL, Lin DX. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis, 2007, 28(5): 1067-1073. [47] O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F, O'Connell J. Targeting the Fas/Fas ligand pathway in cancer. Expert Opinion on Therapeutic Targets, 2005, 9(5): 1031-1044. DOI:10.1517/14728222.9.5.1031 [48] Meng YL, Cai LH, Wu HF, Zhang LN. Immunohistochemical observation on the anti-tumor effect of the Pachyman polysaccharides modified by chemical technique. Medical Journal of Wuhan University, 2007, 28(1): 67-69. (in Chinese)
孟运莲, 蔡丽华, 吴慧芬, 张俐娜. 化学修饰的茯苓多糖抗肿瘤效应的免疫组织化学观察. 武汉大学学报(医学版), 2007, 28(1): 67-69. [49] Liang ZEN, Guo YT, Yi YJ, Wang RC, Hu QL, Xiong XY. Ganoderma lucidum polysaccharides target a Fas/caspase dependent pathway to induce apoptosis in human colon cancer cells. Asian Pacific Journal of Cancer Prevention, 2014, 15(9): 3981-3986. DOI:10.7314/APJCP.2014.15.9.3981 [50] Jiao CW, Chen W, Tan XP, Liang HJ, Li JY, Yun H, He CY, Chen JM, Ma XW, Xie YZ, Yang BB. Ganoderma lucidum spore oil induces apoptosis of breast cancer cells in vitro and in vivo by activating caspase-3 and caspase-9. Journal of Ethnopharmacology, 2020, 247: 112256. DOI:10.1016/j.jep.2019.112256 [51] RodrÍguez E, Schetters STT, Van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nature Reviews Immunology, 2018, 18(3): 204-211. DOI:10.1038/nri.2018.3 [52] Thomas PD, Kahn M. Kat3 coactivators in somatic stem cells and cancer stem cells: biological roles, evolution, and pharmacologic manipulation. Cell Biology and Toxicology, 2016, 32(1): 61-81. DOI:10.1007/s10565-016-9318-0 [53] Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends in Immunology, 2016, 37(3): 208-220. DOI:10.1016/j.it.2016.01.004 [54] Wang XE, Wang YH, Zhou Q, Peng M, Zhang J, Chen M, Ma LJ, Xie GM. Immunomodulatory effect of lentinan on aberrant T subsets and cytokines profile in non-small cell lung cancer patients. Pathology & Oncology Research, 2020, 26(1): 499-505. DOI:10.1007/s12253-018-0545-y [55] Cao QC, Lin ZB, Li WD. Ganoderma lucidum polysaccharide peptide inhibits the growth of mouse LLC implanted tumors by regulating the level of Treg in the tumor microenvironment. Chinese Pharmacological Bulletin, 2015, 31(B11): 220-221. (in Chinese)
蔡庆超, 林志彬, 李卫东. 灵芝多糖肽通过调节肿瘤微环境中Treg水平抑制小鼠LLC种植瘤生长. 中国药理学通报, 2015, 31(B11): 220-221. [56] Kim HS, Kim JY, Kang JS, Kim HM, Kim YO, Hong IP, Lee MK, Hong JT, Kim Y, Han SB. Cordlan polysaccharide isolated from mushroom Cordyceps militaris induces dendritic cell maturation through toll-like receptor 4 signalings. Food and Chemical Toxicology, 2010, 48(7): 1926-1933. DOI:10.1016/j.fct.2010.04.036 [57] Lin ZB. Antitumor effect of Ganoderma (Lingzhi) mediated by immunological mechanism and its clinical application. Chinese Journal of Pharmacology and Toxicology, 2015, 29(6): 865-882. (in Chinese)
林志彬. 灵芝抗肿瘤作用的免疫学机制及其临床应用. 中国药理学与毒理学杂志, 2015, 29(6): 865-882. DOI:10.3867/j.issn.1000-3002.2015.06.001 [58] Liu XD, Li M, Li WX, Wang QY, Zhang HX. Combined effect of lentinan and cisplatin on cytokines IL-6, TNF-α, and TGF-β in tumor therapy. International Journal of Polymer Science, 2019, 2019: 4064703. [59] Sun LX, Lin ZB, Li XJ, Li M, Lu J, Duan XS, Ge ZH, Song YX, Xing EH, Li WD. Promoting effects of Ganoderma lucidum polysaccharides on B16F10 cells to activate lymphocytes. Basic & Clinical Pharmacology & Toxicology, 2011, 108(3): 149-154. [60] Bi SX, Huang WJ, Chen S, Huang CH, Li CL, Guo ZY, Yang JN, Zhu JH, Song LY, Yu RM. Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes. International Journal of Biological Macromolecules, 2020, 150: 261-280. DOI:10.1016/j.ijbiomac.2020.02.050 [61] Chen SD, Yong TQ, Zhang YF, Su JY, Jiao CW, Xie YZ. Anti-tumor and anti-angiogenic ergosterols from Ganoderma lucidum. Frontiers in Chemistry, 2017, 5: 85. DOI:10.3389/fchem.2017.00085 [62] Lu X, Horner JW, Paul E, Shang XY, Troncoso P, Deng PN, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, De Pinho RA. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature, 2017, 543(7647): 728-732. DOI:10.1038/nature21676 [63] 陈国荣. 糖化学基础. 上海: 华东理工大学出版社, 2009.